Study of bloodstream infections caused by Enterococcus bacteria
VENOUS: A Translational Study of Enterococcal Bacteremia
The University of Texas Health Science Center, Houston · NCT04410276
This study is trying to learn more about bloodstream infections caused by Enterococcus bacteria in hospitalized patients to improve future treatments and understand how these infections behave.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Texas Health Science Center, Houston (other) |
| Locations | 12 sites (Miami, Florida and 11 other locations) |
| Trial ID | NCT04410276 on ClinicalTrials.gov |
What this trial studies
This study aims to create a multicenter prospective cohort of hospitalized patients with enterococcal bloodstream infections (BSIs) to gather data on patient outcomes and the characteristics of the bacteria involved. By analyzing enterococcal isolates, the study seeks to understand the molecular epidemiology of these infections, which will inform future clinical trials. The data collected will also assist in sample size calculations for subsequent studies focused on enterococcal BSIs.
Who should consider this trial
Good fit: Ideal candidates include hospitalized patients with at least one positive blood culture for Enterococcus species during their stay.
Not a fit: Patients whose cultures were obtained outside of a hospital setting or whose bacterial isolates are not available for further study may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment of enterococcal bloodstream infections.
How similar studies have performed: While this study focuses on a specific cohort and bacterial characterization, similar observational studies have provided valuable insights into bloodstream infections and their management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized patient * ≥1 positive blood culture with Enterococcus spp. (VRE or VSE) during hospitalization * bacterial isolate(s) is/are available for further characterization * Repeat blood culture(s) within 7 days from the first positive culture Exclusion Criteria: * Cultures obtained from patients not admitted to the hospital * Isolate(s) not available for further studies.
Where this trial is running
Miami, Florida and 11 other locations
- Jackson Health System, University of Miami Miller School of Medicine — Miami, Florida, United States (RECRUITING)
- Henry Ford Hospital and Medical Centers — Detroit, Michigan, United States (RECRUITING)
- University of Mississippi Medical Center — Jackson, Mississippi, United States (RECRUITING)
- University of North Carolina — Chapel Hill, North Carolina, United States (RECRUITING)
- University of Pittsburgh School of Medicine — Pittsburgh, Pennsylvania, United States (RECRUITING)
- MD Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
- The University of Texas Health Science Center at Houston — Houston, Texas, United States (RECRUITING)
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States (RECRUITING)
- Hospital Sanatorio — Buenos Aires, Argentina (RECRUITING)
- Hospital Padre Hurtado — Santiago, Chile (RECRUITING)
- University of Cologne — Cologne, Germany (NOT_YET_RECRUITING)
- Hospital Universitari de Bellvitge — Barcelona, Spain (RECRUITING)
Study contacts
- Principal investigator: Cesar A. Arias, MD, MSc, PhD — The University of Texas Health Science Center, Houston
- Study coordinator: Cesar A. Arias, MD, MSc, PhD
- Email: Cesar.Arias@uth.tmc.edu
- Phone: (713) 500-9000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Enterococcal Bacteremia, entercoccal bloodstream infection, vancomycin-resistant enterococci, vancomycin-susceptible enterococci